Researchers from the National Health Research Institutes have discovered a possible way to improve immunotherapy treatment for pancreatic cancer. Their study focused on blocking a protein called MAP4K2, which appears to reduce the effectiveness of anti-PD-1 therapy, a common type of cancer immunotherapy. Pancreatic cancer is often called the “king of cancers” because it is very difficult to detect early. Most patients are diagnosed at a late stage, leading to very low survival rates. Although anti-PD-1 therapy has helped treat some cancers, it has shown limited efficacy in treating pancreatic cancer. The researchers explained that the immune system contains different types of cells. Cytotoxic T cells attack and destroy cancer cells, while regulatory T cells can weaken the immune response. Cancer tumors often increase the number of regulatory T cells, helping the cancer protect itself from attack. After years of research, scientists created genetically modified mice without the MAP4K2 gene. They found that removing MAP4K2 reduced the number of regulatory T cells and increased the number of cancer-fighting cytotoxic T cells in tumor tissues. The team also tested a treatment that combined anti-PD-1 therapy with a MAP4K2 inhibitor. The combined treatment significantly improved the immune response against pancreatic cancer in mice. Researchers believe MAP4K2 could become an important new target for future cancer immunotherapy treatments.